Effect of subcutaneous Enoxaparin injection duration on bruising size in acute coronary syndrome patients

Khadije Dehghani, Zahra Najari, Hamideh Dehghani, Khadije Dehghani, Zahra Najari, Hamideh Dehghani

Abstract

Background: Bruising is an unpleasant result of subcutaneous injection of Enoxaparin, which causes physical discomfort, limitation of injection site, patient's refusal of treatment, and distrust in nurses' ability. The application of techniques which reduce patients' fear, anxiety, and physical damage is one of the tasks of nurses. This clinical trial investigated the effect of duration of subcutaneous Enoxaparin injection on the bruising size in acute coronary syndrome patients.

Materials and methods: Seventy 35-75-year-old acute coronary syndrome patients hospitalized in Coronary Care Units were selected randomly. Each subject received 10- and 30-sec duration of injections by a single researcher on both sides of the abdomen in 12-h intervals. The bruising size was measured using a transparent millimeter measuring paper, 24 and 48 h after each injection. Data were gathered by a data recording form (demographic and measurements data) and analyzed by descriptive statistics and non-parametric tests through SPSS.

Results: Results showed that the mean bruising sizes at 24 h after 10- and 30-sec injection were 33.26 mm(2) (72.77) and 48.96 mm(2) (99.91), respectively, and at 48 h were 15.61 mm(2) (142.02) and 52.48 mm(2) (143), respectively. There was no significant relationship between the two techniques (P > 0.05), although the effect of age on bruising size was significant (P = 0.01).

Conclusion: According to the findings of the present study, length of Enoxaparin subcutaneous injection has no effect on the bruising size.

Keywords: Acute coronary syndrome; Enoxaparin; bruising; subcutaneous injection.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Verrier J, Deelstra M. Acute coronary syndromes. In: Woods S, editor. Cardiac nursing. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2010. pp. 511–27.
    1. Munro N. Acute coronary syndromes. In: Carlson K, editor. ACCN Advanced critical care nursing. Washington: Elsevier Sunders; 2009. pp. 207–9.
    1. Yavari P, Abadi A, Mehrabi Y. Mortality and changing epidemiological trends in Iran during 1979-2001. Hakim Med J. 2003;6:7–14.
    1. Jolly S, Tan M, Mendelsohn A, Fitchett D, Armstrong PW, Langer A, et al. Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome. Am J Cardiol. 2007;99:186–8.
    1. Fox K, Antman E, Cohen M, Bigonzi F. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol. 2002;90:477–82.
    1. Goodman SG, Bozovich GE, Tan M, Dos Santos A, Gurfinkel EP, Cohen M, et al. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: The Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy. Am Heart J. 2006;151:791–7.
    1. Anderson JA, Hirsh J, Yusuf S, Johnston M, Afzal R, Mehta SR, et al. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. J Thromb Haemost. 2010;8:243–9.
    1. Cohen M, Levine GN, Pieper KS, Lan L, Antman EM, Aylward PE, et al. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial. Catheter Cardiovasc Interv. 2010;75:928–35.
    1. Brosa M, Rubio-Terrés C, Farr I, Nadipelli V, Froufe J. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome. Pharmacoeconomics. 2002;20:979–87.
    1. Orlewska E, Budaj A, Tereszkowski-Kaminski D. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective. Pharmacoeconomics. 2003;21:737–48.
    1. Spyropoulos A, Frost F, Hurley J, Roberts M. Oral anticoagulant therapy bridging in patients receiving long-term unfractionated Heparin for perioperative with low-molecular-weight heparin vs costs and clinical outcomes associated. Chest. 2004;125:1642–50.
    1. Lehne R. 6th ed. St. Louis: Sunders Elsevier; 2007. Pharmacology for nursing care; pp. 592–3.
    1. Schindewolf M, Schwaner S, Wolter M, Kroll H, Recke A, Kaufmann R, et al. Incidence and causes of heparin-induced skin lesions. CMAJ. 2009;181:477–81.
    1. Dalainas I, Avgerinos ED, Liapis CD. Heparin-induced thrombocytopenia: What a vascular surgeon needs to know. J Cardiovasc Surg (Torino) 2011;52:81–8.
    1. Alban S. Adverse effects of heparin. Handb Exp Pharmacol. 2012;207:211–63.
    1. Chan H. Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin. J Adv Nurs. 2001;35:882–92.
    1. Kuzu N, Ucar H. The effect of cold on the occurrence of bruising, hematoma and pain at the injection site in subcutaneous low molecular weight heparin. Int J Nurs Stud. 2001;38:51–9.
    1. Chenicek T. Effects of injection duration on site-pain intensity and bruising associated with subcutaneous administration of Lovenox (Enoxaparin sodium). MSc Nursing thesis. Electronic Theses, Treatises and Dissertations. 2004. [Last accessed on 2013]. Paper 3825. Available from: .
    1. Balci Akpinar R, Celebioglu A. Effect of injection duration on bruising associated with subcutaneous heparin: A quasi-experimental within-subject design. Int J Nurs Stud. 2008;45:812–7.
    1. Nair P, Kaur S, Sharma YP. Effect of time taken in injecting subcutaneous heparin injection with reference to site pain and bruising among patients receiving heparin therapy. Nurs Midwifery Res J. 2008;4:7–15.
    1. Babaie Asl F, Kheradmand M, Jafarian R. Effect of duration of subcutaneous heparin injection on its subsequent pain. Feyz J Kashan Univ Med Sci. 2008;12:34–8.
    1. Palese A, Aidone E, Dante A, Pea F. Occurrence and Extent of Bruising According to Duration of Administration of Subcutaneous Low-Molecular-Weight. Heparin J Cardiovasc Nurs. 2013;28:473–82.
    1. Zaybak A, Khorshid L. A study on the effect of the duration of subcutaneous heparin injection on bruising and pain. J Clin Nurs. 2008;17:378–85.
    1. Ebersole P, Hess P. 4th ed. St. Louis: Mosby; 2004. Geriatric nursing and healthy aging; pp. 142–6.
    1. Trimarchi S, Smith DE, Share D, Jani SM, O’Donnell M, McNamara R, et al. Retroperitoneal Hematoma after Percutaneous Coronary Intervention: Prevalence, Risk Factors, Management, Outcomes, and Predictors of Mortality. JACC Cardiovasc Interv. 2010;3:845–50.
    1. Antman E, Morrow D, McCabe C, Murphy S, Ruda M, Sadowski Z, et al. Enoxaparin Versus Unfractionated Heparin With Fibrinolysis for ST-elevation Myocardial Infarction. N Engl J Med. 2006;354:1477–88.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する